Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Darapladib

Generic Name: Darapladib

Drug Type: Small Molecule

Chemical Formula: C_₃₆H_₃₈F_₄N_₄O_₂S

CAS Number: 356057-34-6

Unique Ingredient Identifier: UI1U1MYH09

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in atherosclerosis.

Associated Conditions

No associated conditions information available.

Clinical Trials

Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Completed

Posted: 2014/02/10

Sponsor:GlaxoSmithKline

ID:NCT02058641

Darapladib China PK

Phase 1

Completed

Posted: 2013/12/04

Sponsor:GlaxoSmithKline

ID:NCT02000804

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

Phase 1

Completed

Posted: 2013/06/10

Sponsor:GlaxoSmithKline

ID:NCT01873339

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

Phase 1

Completed

Posted: 2013/05/13

Sponsor:GlaxoSmithKline

ID:NCT01852565

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

Phase 1

Completed

Posted: 2012/12/17

Sponsor:GlaxoSmithKline

ID:NCT01751074

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy